Shilpa Medicare530549Pharmaceuticals, CDMO services
Shilpa Medicare rose about 4.5% after its partner Unicycive Therapeutics received USFDA acceptance of a resubmitted NDA application for a chronic kidney disease drug
By ScoutQuest · · 1 min read
- Stock move today
- almost 5 percent
- Stock move today (update)
- around 4 and 1/2 percent
Heard on business television between 12:04:20 - 12:07:20 IST.
- Shilpa Medicare's partner, biotechnology company Unicycive Therapeutics, had its resubmission letter for an initial NDA application accepted by the USFDA
- The drug is for chronic kidney disease, resubmitted after a complete response letter
- Shilpa Medicare provides end-to-end CDMO services to Unicycive, including API development, formulation and supply of finished dosages
- The two have had a long-term supply agreement since Q1 FY26
- Street is watching for the drug to reach an approval stage with USFDA; stock up about 4.5 percent
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Shilpa Medicare
Shilpa Medicare gained 2% after one of its plants received a USFDA approval or acceptance letter for a key drug
22 Oct 2026
Viewer asked about entering Shilpa Medicare after a 2.7% decline; analyst said wait for the fall to stabilize before buying
15 Oct 2026
Nimesh flagged possible buying by a large global sovereign fund in Shilpa Medicare at current levels
14 Oct 2026
Source: Live TV News Channel · 22 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.